Deferasirox DFX, DT + Erythropoietin alpha + Deferasirox DFX, FCT
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low and Int 1-risk Myelodysplastic Syndrome
Conditions
Low and Int 1-risk Myelodysplastic Syndrome
Trial Timeline
Jan 28, 2014 → Apr 5, 2017
NCT ID
NCT01868477About Deferasirox DFX, DT + Erythropoietin alpha + Deferasirox DFX, FCT
Deferasirox DFX, DT + Erythropoietin alpha + Deferasirox DFX, FCT is a phase 2 stage product being developed by Novartis for Low and Int 1-risk Myelodysplastic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01868477. Target conditions include Low and Int 1-risk Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01868477 | Phase 2 | Completed |